Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 2, 2012, Pages 206-212

  Chakravarty, Soumya D ^a   Harris, Mary E ^a   Schreiner, Andrew M ^a   Crow, Mary K ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE;

ADULT; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; BRONCHUS BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHADENOPATHY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; SARCOIDOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INTERFERON-BETA; METHOTREXATE; MULTIPLE SCLEROSIS; PREDNISONE; RADIOGRAPHY, THORACIC; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84866501017     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.03.008     Document Type: Article

References (23)

1. Chatham W. Rheumatic manifestations of systemic disease: Sarcoidosis. Curr Opin Rheumatol 2010, 22(1):85-90.
2. Abdi E.A., Nguyen G.K., Ludwig R.N., Dickout W.J. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987, 59(5):896-900.
3. Bobbio-Pallavicini E., Valsecchi C., Tacconi F., Moroni M., Porta C. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995, 12(2):140-142.
4. Mehta C.L., Tyler R.J., Cripps D.J. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol 1998, 39(6):1024-1028.
5. O'Reilly S., White A., Florian A. Mediastinal sarcoidosis in a patient receiving inferon-beta for multiple sclerosis. Chest 2005, 128(4):450S.
6. Crow M.K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010, 12(Suppl 1):S5.
7. Buttmann M., Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007, 7(3):227-239.
8. Mirandola S.R., Hallal D.E., Farias A.S., Oliveira E.C., Brandão C.O., Ruocco H.H., et al. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 2009, 9(7-8):824-830.
9. van Baarsen L.G., van der Pouw Kraan T.C., Kragt J.J., Baggen J.M., Rustenburg F., Hooper T., et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006, 7(6):522-531.
10. van Baarsen L.G., Vosslamber S., Tijssen M., Baggen J.M., van der Voort L.F., Killestein J., et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients. PLoS ONE 2008, 3(4):e1927.
11. Al-Masri A.N., Heidenreich F., Walter G.F. Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients. Eur J Neurol 2009, 16(6):721-726.
12. Lande R., Gafa V., Serafini B., Giacomini E., Visconti A., Remoli M.E., et al. Plasmacytoid dendritic cells in multiple sclerosis: Intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol 2008, 67(5):388-401.
13. Traugott U., Lebon P. Multiple sclerosis: Involvement of interferons in lesion pathogenesis. Ann Neurol 1988, 24(2):243-251.
14. Comabella M., Lunemann J.D., Rio J., Sanchez A., Lopez C., Julia E., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132(12):3353-3365.
15. Groom J.R., Luster A.D. CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011, 89(2):207-215.
16. Proudfoot A.E. Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol 2002, 2(2):106-115.
17. Agostini C., Cassatella M., Zambello R., Trentin L., Gasperini S., Perin A., et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 1998, 161(11):6413-6420.
18. Sugiyama K., Mukae H., Ishii H., Kakugawa T., Ishimoto H., Nakayama S., et al. Elevated levels of interferon gamma-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. Respirology 2006, 11(6):708-714.
19. Takeuchi M., Oh I.K., Suzuki J., Hattori T., Takeuchi A., Okunuki Y., et al. Elevated serum levels of CXCL9/monokine induced by interferon-gamma and CXCL10/interferon-gamma-inducible protein-10 in ocular sarcoidosis. Invest Ophthalmol Vis Sci 2006, 47(3):1063-1068.
20. Akahoshi M., Ishihara M., Remus N., Uno K., Miyake K., Hirota T., et al. Association between IFNα genotype and the risk of sarcoidosis. Hum Genet 2004, 114(5):503-509.
21. Sweiss N.J., Zhang W., Franek B.S., Kariuki S.N., Moller D.R., Patterson K.C., et al. Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry. PLoS ONE 2011, 6(12):e29126.
22. Alazemi S., Campos M.A. Interferon-induced sarcoidosis. Int J Clin Pract 2006, 60(2):201-211.
23. Doyle M.K., Berggren R., Magnus J.H. Interferon-induced sarcoidosis. J Clin Rheumatol 2006, 12(5):241-248.